VEGFA and hepatocellular carcinoma: In this regard, a combination therapy of the VEGF-targeting monoclonal antibody bevacizumab with the immune checkpoint inhibitor (ICI) atezolizumab has shown very promising effects on the survival of unresectable HCC patients in a phase 3 trial [10].